Datasets
Models
Downloads: 1
Diff of
/clusters/9knumclustersv2/clust_1539.txt
[000000]
..
[c09aa8]
Switch to unified view
| a | b/clusters/9knumclustersv2/clust_1539.txt | ||
|---|---|---|---|
| 1 | Treatment with any of the following for prostate cancer within weeks prior to day of treatment: |
||
| 2 | Prior systemic chemotherapy for prostate cancer. |
||
| 3 | Prior cytotoxic chemotherapy for metastatic prostate cancer; prior treatment with genomically-targeted agents, or Provenge is allowed |
||
| 4 | History of prior treatment for prostate cancer. |
||
| 5 | Subject has received prior radiation therapy or chemotherapy for prostate cancer |
||
| 6 | Prior systemic chemotherapy for prostate cancer. |
||
| 7 | Prior systemic chemotherapy for prostate cancer |
||
| 8 | Previous chemotherapy for prostate cancer |
||
| 9 | Prior cytotoxic chemotherapy or biologic therapy for prostate cancer |
||
| 10 | Prior radiation to the prostate |
||
| 11 | Previous or concurrent cytotoxic chemotherapy for prostate cancer |
||
| 12 | Patients who have had any prior chemotherapy or radiotherapy for prostate cancer. |
||
| 13 | No treatment with any of the following for prostate cancer within weeks prior to enrollment: |
||
| 14 | No prior chemotherapy for prostate cancer |
||
| 15 | Prior immunotherapy or chemotherapy for prostate cancer |
||
| 16 | Prior immunotherapy/vaccine therapy for prostate cancer |
||
| 17 | Patients who have had prior chemotherapy for prostate cancer |
||
| 18 | Prior history of treated prostate cancer |
||
| 19 | Previous or concurrent cytotoxic chemotherapy for prostate cancer |
||
| 20 | Patients who have had prior chemotherapy, experimental agents for prostate cancer, or patients receiving more than weeks of prior hormone therapy will be excluded |
||
| 21 | Prior or concurrent cytotoxic chemotherapy for prostate cancer; prior chemotherapy for a different cancer is permitted |
||
| 22 | Prior systemic chemotherapy for prostate cancer |
||
| 23 | Prior or current therapy for prostate cancer |
||
| 24 | No prior treatment for prostate cancer |
||
| 25 | Prior chemotherapy for prostate cancer |
||
| 26 | Prior systemic biologic therapy, including immunotherapy, for prostate cancer; |
||
| 27 | Prior definitive treatment of prostate cancer |
||
| 28 | Prior chemotherapy or immunotherapy for prostate cancer. |
||
| 29 | Prior use of immunotherapy or chemotherapy for prostate cancer |
||
| 30 | Prior radiation therapy for prostate cancer |
||
| 31 | Prior investigational therapy for prostate cancer |
||
| 32 | Prior or concurrent cytotoxic chemotherapy for prostate cancer; prior chemotherapy for a different cancer is permitted |
||
| 33 | No prior systemic therapy for metastatic prostate cancer |
||
| 34 | Prior chemotherapy, radiation therapy, or immunotherapy for prostate cancer |
||
| 35 | Treatment with more than one chemotherapy agent for prostate cancer |
||
| 36 | Treatment with cytotoxic chemotherapy for prostate cancer within the previous weeks prior to randomization, or planned treatment with cytotoxic chemotherapy agents for prostate cancer during the treatment period or follow-up |
||
| 37 | COHORT A: Current or prior investigational therapies for prostate cancer, or chemotherapy administered with the intention to treat prostate cancer |
||
| 38 | COHORT B: Current or prior investigational therapies for prostate cancer, or chemotherapy administered with the intention to treat prostate cancer |
||
| 39 | More than prior courses of chemotherapy for metastatic prostate cancer |
||
| 40 | Patients with prior chemotherapy for nonmetastatic prostate cancer within a year are excluded |
||
| 41 | No prior radiation or chemotherapy for prostate cancer treatment |
||
| 42 | Prior cytotoxic chemotherapy or biologic therapy for prostate cancer |
||
| 43 | Patients must not have been treated with a prior vaccine therapy for prostate cancer |
||
| 44 | E . Prior chemotherapy for prostate cancer, |
||
| 45 | Previous or concurrent cytotoxic chemotherapy for prostate cancer |
||
| 46 | Prior cytotoxic chemotherapy for metastatic prostate cancer |
||
| 47 | Prior chemotherapy for prostate cancer |
||
| 48 | Have had prior or current prostate cancer therapies: |
||
| 49 | Chemotherapy for prostate cancer |
||
| 50 | Prior chemotherapy for prostate cancer |
||
| 51 | Prior chemotherapy, radiation therapy for the treatment of prostate cancer, or immunotherapy for prostate cancer |
||
| 52 | Any prior or concurrent treatment for prostate cancer |
||
| 53 | Prior surgery or radiation therapy for prostate cancer |
||
| 54 | Prior history of prostate cancer |
||
| 55 | SUB-STUDY I: Chemotherapy for prostate cancer |
||
| 56 | SUB-STUDY II: Chemotherapy for prostate cancer |
||
| 57 | Patient must not have had any prior treatment for prostate cancer |
||
| 58 | Patients who have received any prior therapy for prostate cancer with surgery, radiation, and/or chemotherapy |
||
| 59 | Chemotherapy for prostate cancer |
||
| 60 | Patients who have had chemotherapy or radiotherapy within months of the study for other diagnoses not related to prostate cancer |
||
| 61 | No prior treatment for prostate cancer |
||
| 62 | Prior treatment for prostate cancer |
||
| 63 | Patients who have received systemic chemotherapy for prostate cancer will not be eligible |
||
| 64 | Any prior treatment for prostate cancer |
||
| 65 | Concurrent immunotherapy for prostate cancer |